Retinol & Retinoids in Skincare: A Comprehensive Guide

Retinoids are among the most extensively studied functional ingredients in skincare. Backed by decades of peer-reviewed research, they are associated with improvements in fine lines, skin texture, hyperpigmentation, and acne. Yet the term "retinoid" covers a broad family of compounds with very different potencies, regulatory statuses, and tolerability profiles. Understanding the differences is essential for making sense of product labels, regulatory restrictions, and evidence-based formulation choices.

The Retinoid Family: From Esters to Retinoic Acid

All retinoids ultimately derive their activity from retinoic acid (tretinoin), which is the form that directly binds to nuclear retinoic acid receptors (RARs) and regulates gene expression. The various retinoid forms used in cosmetics and medicine differ primarily in how many enzymatic conversion steps are required before retinoic acid is produced in the skin.

The conversion pathway proceeds in one direction only:

Retinyl esters (e.g., retinyl palmitate) → Retinol → Retinal (retinaldehyde) → Retinoic acid

Each conversion step involves specific enzymes and occurs within skin cells. Because each step is rate-limited, forms further from retinoic acid are less efficient — they require higher concentrations and longer timelines to produce equivalent biological effects. However, this same inefficiency is partly responsible for their milder irritation profiles.

Retinyl Esters (Retinyl Palmitate, Retinyl Acetate)

Retinyl esters are the most stable and least irritating retinoid forms used in cosmetics. Retinyl palmitate is the ester of retinol with palmitic acid and is widely used in moisturisers and daily-use products. Because two enzymatic steps are required to reach retinoic acid, retinyl esters show the lowest potency per unit concentration among the retinoid family. They are primarily used in formulations targeting mild improvements or in products designed for frequent use by those new to retinoids.

The Cosmetic Ingredient Review (CIR) has assessed retinyl palmitate and retinyl acetate as safe for use in cosmetics at current concentrations used in the industry.

Retinol

Retinol is the alcohol form of vitamin A and the most widely recognised retinoid in over-the-counter skincare. It requires conversion to retinal and then to retinoic acid. Clinical studies — including a landmark 1995 study by Kang et al. in the Journal of Investigative Dermatology — have demonstrated that topical retinol applied to human skin induces changes in epidermal gene expression similar to those produced by retinoic acid, without producing measurable retinoic acid levels in skin or systemic circulation. This finding underlies the rationale for retinol's use as a cosmetically active ingredient across jurisdictions where retinoic acid is prescription-only.

Clinical evidence supports retinol's efficacy for:

• Reduction in the appearance of fine lines and wrinkles after 12–24 weeks of consistent use
• Improvement in skin texture and pore appearance
• Supporting skin cell turnover (desquamation) processes
• Mild improvement in hyperpigmentation when used consistently

Retinal (Retinaldehyde)

Retinal (retinaldehyde) is positioned one step closer to retinoic acid in the conversion pathway. It requires only a single enzymatic oxidation step to become retinoic acid. As a result, studies suggest retinal is approximately 10–20 times more potent than retinol on a concentration basis, while remaining less irritating than prescription-strength tretinoin. Retinal has gained significant attention from formulators and researchers, particularly in the context of efficacy at lower concentrations. It also has direct antimicrobial properties that may be relevant in acne-prone skin formulations.

Tretinoin (Retinoic Acid / All-Trans Retinoic Acid)

Retinoic acid (tretinoin) is the pharmacologically active form that directly activates RARs. It does not require conversion and is significantly more potent per unit concentration than retinol or retinyl esters. In the United States, tretinoin is classified as a prescription drug (Rx-only). In the European Union, it is regulated as a medicinal product when used at therapeutic concentrations. In Japan, tretinoin is classified as a pharmaceutical and is not permitted in cosmetic products.

Because it bypasses all enzymatic conversion steps, tretinoin produces faster results but also carries a higher likelihood of irritation, dryness, peeling, and initial purging — particularly at concentrations above 0.025%.

Adapalene and Tazarotene

Adapalene is a third-generation synthetic retinoid with selective RAR-β and RAR-γ agonism. It is available over-the-counter in the US at 0.1% for acne treatment and is notably more stable and less irritating than tretinoin at equivalent concentrations. Tazarotene is a receptor-selective retinoid approved for acne and psoriasis; it is available by prescription in most markets and is considered among the most potent topical retinoids. Neither adapalene nor tazarotene is generally classified as a cosmetic ingredient — both carry drug regulatory status in the markets where they are approved.

Efficacy Hierarchy

Form	Conversion Steps to Retinoic Acid	Relative Potency	Regulatory Status (US)	Irritation Potential
Tretinoin (retinoic acid)	0 (active form)	Highest	Prescription drug	High
Tazarotene	0 (pro-drug, rapid conversion)	Very high	Prescription drug	High
Retinal (retinaldehyde)	1	High	Cosmetic (OTC)	Moderate
Adapalene	0 (direct RAR agonist)	High	OTC drug (0.1%)	Low–Moderate
Retinol	2	Moderate	Cosmetic (OTC)	Low–Moderate
Retinyl esters	3	Low	Cosmetic (OTC)	Low

Regulatory Landscape by Region

European Union

The EU regulates cosmetic ingredients under Regulation (EC) No 1223/2009. Following a 2016 SCCS opinion on vitamin A (updated with an additional opinion in 2022), the European Commission adopted Regulation (EU) 2022/1181, which set new concentration limits effective from January 2023.

Key EU restrictions for retinol and retinyl esters (expressed as retinol equivalents):

• Face products: Maximum 0.3% retinol equivalent
• Hand and body lotions: Maximum 0.05% retinol equivalent
• Products for children under 3 years: Retinol must not be used
• Products for pregnant women: Labelling warnings recommended
• Rinse-off products: Restrictions apply based on use category

These restrictions apply to retinol and retinyl esters used in cosmetics. Retinoic acid (tretinoin) is not permitted in cosmetics in the EU and is regulated as a medicinal product.

United States

Under US law, cosmetic products are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act. Retinol and retinyl esters are not subject to specific concentration limits when used in cosmetics and are freely available in OTC products. However, claims made about a product determine its regulatory classification: products claiming to treat or prevent a disease or to affect the structure or function of the body may be reclassified as drugs, requiring premarket approval.

Tretinoin (retinoic acid) is an FDA-approved prescription drug for acne (Retin-A) and photoaging (Renova). It is not available OTC in the United States.

Japan

In Japan, the MHLW (Ministry of Health, Labour and Welfare) oversees both cosmetics (化粧品) and quasi-drugs (医薬部外品). Retinol is permitted in cosmetics without specific concentration restrictions, but claims are tightly regulated — a cosmetic product cannot claim to alter skin structure or function. Quasi-drug status allows more specific functional claims (such as improving fine lines or supporting anti-aging), but requires regulatory approval of both the formulation and the claims.

Tretinoin is classified as a pharmaceutical in Japan and is not permitted in cosmetics or quasi-drugs. Some retinol derivatives are used in quasi-drug formulations under specific approved conditions.

Starting Concentrations and Building Tolerance

A common evidence-based approach to introducing retinoids is a "start low, go slow" protocol. Researchers and cosmetic chemists generally suggest:

• Beginner range: 0.025% to 0.1% retinol, applied 2–3 times per week in the evening
• Intermediate range: 0.1% to 0.3% retinol after 4–8 weeks of consistent low-dose use
• Advanced use: 0.3% to 0.5% retinol for those with established tolerance; above 0.3% falls outside EU face product limits

The buffering method — applying a moisturiser before retinol — may reduce irritation for those with sensitive skin, though some studies suggest it may also reduce efficacy somewhat by diluting skin penetration. Research published in peer-reviewed dermatology literature supports the view that applying retinol to dry (not damp) skin reduces penetration speed and thereby irritation, though this remains a point of ongoing study.

Understanding Purging

"Purging" refers to an initial period — typically 4–8 weeks — during which comedones and microcomedones that already existed beneath the skin surface are rapidly expelled due to accelerated cell turnover. This is a normal response to retinoid use and is distinct from a product-triggered breakout. True purging tends to occur in areas where an individual already experiences breakouts and resolves within the adaptation window. Breakouts appearing in entirely new areas, or persisting beyond 8 weeks, may suggest a different reaction.

Sun Sensitivity Considerations

Retinoids increase cell turnover, which transiently reduces the thickness of the stratum corneum, the outermost protective skin layer. This can increase susceptibility to UV damage. Studies consistently recommend applying retinoid products in the evening and using broad-spectrum sunscreen with at least SPF 30 daily when using retinoid-containing products. This is reflected in product labelling guidance across the EU, US, and Japan.

Formulation Stability

Retinol and retinal are notably unstable molecules. They degrade on exposure to air, light, and heat through oxidation, converting into inactive forms. Formulators address this through:

• Encapsulation technologies (liposomes, microspheres) that release retinol gradually
• Opaque, airless packaging to minimise oxidative exposure
• Combination with antioxidants such as tocopherol (vitamin E) to stabilise the formula
• Anhydrous (waterless) formulations that slow hydrolytic degradation

Retinyl palmitate is inherently more stable than retinol or retinal due to the esterification of the hydroxyl group. However, this stability comes at the cost of efficacy.

Key Takeaways

• All retinoids in the cosmetic-to-pharmaceutical spectrum work by ultimately delivering retinoic acid to skin cells; forms closer to retinoic acid are more potent and more irritating
• The EU imposes strict concentration limits on retinol in cosmetics (0.3% face, 0.05% body) as of January 2023; the US does not set concentration limits for cosmetic retinol; Japan permits retinol in cosmetics without specific limits
• Tretinoin is prescription-only in the US and Japan, and not permitted in EU cosmetics
• Starting concentrations of 0.025–0.1% retinol, used a few nights per week, reflect a standard evidence-based approach to building tolerance
• Retinoid use requires consistent SPF application during the day